# A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

> **NCT00445198** · PHASE1,PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 86 (actual)

## Conditions studied

- Small Cell Lung Cancer
- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** ABT-263

## Key facts

- **NCT ID:** NCT00445198
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2018-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445198, "A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00445198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*